Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early syndecan-4 upregulation predicts cognitive and pathological trajectories in Alzheimer disease.

Alzheimer's research & therapy·2026
Same author

Usage and positivity rates of Alzheimer's disease biomarkers in a memory clinic.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

<i>Trans</i>-eQTLs reveal the architecture of human gene regulatory networks.

medRxiv : the preprint server for health sciences·2026
Same author

Low overlap of plasma and CSF protein quantitative trait loci affects protein discovery for neurological disease.

Science translational medicine·2026
Same author

GPND-AI NULISA: A 15-Protein AI classifier for diagnosis and co-pathology profiling across neurodegenerative diseases.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

[11C]CS1P1 PET links T-cell-associated immune activation with endothelial and astrocytic responses.

Research square·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Correlates and predictors of self-efficacy among dementia caregivers: D-CARE findings.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

What should convince a clinician of disease modification in Alzheimer's disease clinical trials?

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Primary cilia-extracellular vesicle crosstalk in Alzheimer's disease: Emerging mechanisms and biomarker potential.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Katherine Gong1,2, Jigyasha Timsina1,2, Muhammad Ali1,2

  • 1Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 24, 2025
PubMed
Summary
This summary is machine-generated.

This study identified 78 plasma proteins linked to Alzheimer's disease (AD) and validated plasma pTau217 as a biomarker. The Nucleic acid Linked Immuno-Sandwich Assay (NULISA) platform shows promise for diagnosing neurodegenerative diseases.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Area of Science:

  • Neuroscience
  • Biochemistry
  • Biomarker Discovery

Background:

  • Plasma assays offer minimally invasive biomarkers for neurodegenerative diseases.
  • The Nucleic acid Linked Immuno-Sandwich Assay (NULISA) platform was used to quantify 123 plasma proteins.
  • The study included over 3,000 individuals with Alzheimer's disease (AD), dementia with Lewy bodies (DLB), frontotemporal dementia (FTD), Parkinson's disease (PD), and controls.

Purpose of the Study:

  • To identify general and disease-specific plasma protein biomarkers for neurodegeneration.
  • To evaluate the performance of the NULISA platform in quantifying these biomarkers.
  • To correlate plasma protein levels with established neuroimaging and fluid biomarkers.

Main Methods:

  • Quantification of 123 plasma proteins in 3,668 samples using NULISA.
  • Differential abundance, ROC, and AUC analyses were performed for AD, DLB, FTD, and PD.
  • Analyses included correlations with amyloid PET, tau PET, CSF Aβ42/Aβ40, and CDR scores.

Main Results:

  • 78 proteins associated with AD, 2 with DLB, 2 with FTD, and 1 with PD.
  • Plasma pTau217 showed high accuracy (AUC 0.81 for AD, 0.95 for amyloid positivity).
  • High concordance (93.59%) between plasma pTau217 and Centiloid levels was achieved.

Conclusions:

  • NULISA is a reliable platform for quantifying plasma proteins in neurodegenerative diseases.
  • Plasma pTau217 is a validated predictive biomarker for AD, correlating strongly with neuroimaging markers.
  • These findings support NULISA's potential for research and clinical applications in neurodegenerative disease diagnostics.